岁月不居，芳华有信。当奔赴科技创新、强国有我的每个不寻常日子里，中医内科学教育部重点实验室全体成员携手奋进、共同努力，在确保数量稳定的基础上，学术论文发表质量不断攀升。 2022年共计发表学术论文157篇，SCI收录67篇，影响因子合计442.43，中科院分区1区28篇，2区18篇，单篇最高影响因子42.439；中文期刊90篇，均为核心期刊。 今年，正值重点实验室成立20周年之际，全体同仁将传承创新发展、求新求实求是、攻坚克难、砥砺前行、凝心聚力，以更加旺盛的斗志、奋发的姿态和充沛的干劲，向着既定目标持续迈进！
英 文 文 章 1. 心血管病方向 [1]Ma X, Liu J, Liu C, Sun W,Duan W, Wang G, Kurihara , He R*, Li Y*,Chen Y*, Shang H*. ALOX15-launched PUFA-phospholipids peroxidation increasesthe susceptibility of ferroptosis in ischemia-induced myocardial damage. SignalTransduct Target Ther. 2022 Aug 15;7(1):288. doi: 10.1038/s41392-022-01090-z. (SCI收录，一区，IF 38.104) .........................................1 [2]Su X#,Zhang X#, Liu W, Yang X, An N, Yang F, Sun J, Xing Y*, Shang H*.Advances in the application of nanotechnology in reducing cardiotoxicityinduced by cancer chemotherapy.Semin Cancer Biol.2022 Nov;86(Pt 2):929-942.(SCI收录，一区，IF 17.012)...........................................................................................................................2 [3] Lv S#,Wang Y, Zhang W, Shang H*. Trimethylamine oxide: a potential target forheart failure therapy.Heart.2022 May25;108(12):917-922. (SCI收录，IF 7.365)………………………………………………………………………………....3 [4] Jiang Y, Wang L, Lu Z, ChenS, Teng Y, Li T, Li Y, Xie Y*, Zhao M*. Brain Imaging Changes andRelated Risk Factors of Cognitive Impairment in Patients With HeartFailure.Front Cardiovasc Med.2022 Jan 26;8:838680.（SCI收录，IF 6.05）.......................................................................................................4 [5]Han XW#, Li T#, Wang TS, Wang BF, LiY, Wang L, Lu ZW, Wu AM, Liu LS, Pan GZ, Zhao MJ*. CirculatingMicroparticles are Associated with Plaque Burden and Cause eNOS Uncoupling inPatients with Carotid Atherosclerosis.Front Pharmacol.2022 Nov 3;13:976644.（SCI收录，一区，IF 5.988）.....5 [6] Lv S, Wang Y, Zhang W, Shang H*. The chemical components,action mechanisms, and clinical evidences ofYiQiFuMai injection in the treatment of heart failure.Front Pharmacol. 2022 Nov24;13:1040235. doi: 10.3389/fphar.2022.1040235. （SCI收录，一区，IF 5.988）................................................................................6 [7] Li T#,Wang B#, Ding H#, Chen S, Cheng W, Li Y, WuX, Wang L, Jiang Y, Lu Z,Teng Y, Su S, Han X, Zhao M*. Effect ofExtracellular Vesicles From Multiple Cells on Vascular Smooth Muscle Cells inAtherosclerosis.Front Pharmacol.2022 May 10;13:857331.（SCI收录，一区，IF5.988）...........................................................7 [8]Wang B#, Teng Y#, Li Y#, Lai S, Wu Y, Chen S, LiT, Han X, Zhou H, Wang Y, Lu Z, Li H, Ding Y, Ma L, Zhao M*, Wang X*.Evidence and Characteristics of Traditional Chinese Medicine for Coronary HeartDisease Patients With Anxiety or Depression: A Meta-Analysis and SystematicReview.Front Pharmacol.2022 May 5;13:854292.（SCI收录，一区，IF 5.988）.............................................................................................8 [9] An N#, Zhang G#Li Y#, Yuan C, Yang F, Zhang L*, Gao Y*, Xing Y*.Promising Antioxidative Effect of Berberine in Cardiovascular Diseases. FrontPharmacol. 2022 Mar 7;13:86535（SCI收录, 一区，IF 5.988）.........................................................9 [10] Li MX, Liu CR, Chen M, Shang H,Wang W, Luo XC, Li L, Qi YN, Xiong YQ, Huang SY, Wang J, Zou K, Liu XH, Tan J*, Sun X*. Effects of MotherwortInjection Versus Intramuscular Oxytocin for Preventing Postpartum HemorrhageAmong Women Who Underwent Cesarean Section. Front Pharmacol. 2022;13:859495.（SCI收录，一区，IF 5.988）.......................................................................................................10 [11]Dai H#, Li H#, Wang B, Zhang J, Chen Y,Zhang X, Liu Y*, Shang H*. Efficacy of pharmacologic therapies inpatients with acute heart failure: A network meta-analysis.Front Pharmacol.2022Sep 23;13:677589.（SCI收录，一区，IF 5.988）.........................................................................................................................11 [12] YangX#, Gokulnath P#, Lehmann HI, Hou Z, YangS, You L, Zhang G, Xing Y, Lei J, Li G*, Guo S*, Shang H*. RNAmodifications in aging-associated cardiovascular diseases.Front Pharmacol.2022Sep 23;13:677589. （SCI收录，一区，IF 5.988）....................................................................................................................12 [13] Wei XH, Wu YZ, Pan HE , Zhang Q, He K, Xia GY, Xia H,Lin S*,Shang H*.Proteomics revealed that mitochondrial function contributed to the protectiveeffect of herba Siegesbeckiae against cardiac ischemia/reperfusion injury.FrontCardiovasc Med.2022 Jul 6;9:895797.（SCI收录，IF 5.846).....................................................13 [14] Jia DD, Zhang XY, Guo QQ, Yang R, Yu HT, Zhao MZ, ShiL, Liu MH, Wu AM*,Zhang DM*. The Efficacy and Underlying Mechanism ofBerberine against Atherosclerosis: a Meta-analysis in Preclinical AnimalStudies .J Cardiovasc Pharmacol.2022 Sep 1;80(3):476-488.（SCI收录，IF3.271）...............................14 [15] Li T#, Han X#,Chen S#, Wang B, Teng Y, Cheng W, Lu Z, Li Y, Wu X, Jiang Y,Wang L, Liu L, Zhao M*. Effects of Exercise on Extracellular Vesicles inPatients with Metabolic Dysfunction: a Systematic Review. J Cardiovasc TranslRes.2022 Jun 2.（SCI收录，IF 3.22）...............................................................................................15 [16] Meng H, Cheng W, Wang L, Chen S, Teng Y, Lu Z,Li Y*, Zhao M*. Mesenchymal Stem Cell Exosomes in the Treatmentof Myocardial Infarction: a Systematic Review of Preclinical In Vivo Studies.JCardiovasc Transl Res.2022 Apr;15(2):317-339.（SCI收录，IF 3.22）...............................................................16 [17] Lv M#, YangD#, Ji XD#, Lou LX, Nie B, Zhao JL, WuAM*, Zhao MJ. Effect of WenXin KeLi on improvement of arrhythmia afterMyocardial infarction by intervening PI3K-AKT-mTOR autophagy pathway. EvidBased Complement Alternat Med.2022 Sep 29;2022:2022970.（SCI收录，IF 2.650）......................................17 [18] Chen S*, Wu X, Li T, Cheng W, Han X, Li Y,Wang B, Teng Y*, Zhao M*, Wang Y*. The Improvement of Cardiac andEndothelial Functions of Xue-Fu-Zhu-Yu Decoction for Patients with AcuteCoronary Syndrome: A Meta-Analysis of Randomized Controlled Trials. Evid BasedComplement Alternat Med.2022 Feb 10;2022:2671343.（SCI收录，IF2.650）..............................................................18 2.脑血管病方向 [19] Li Y#, Liu H#, Tian C#, An N, Song K, Wei Y, SunY, Xing Y*, Gao Y*. Targeting the multifaceted roles of mitochondria inintracerebral hemorrhage and therapeutic prospects. Biomed Pharmacother. 2022Apr;148:112749.（SCI收录，IF 7.419）……………………………………………………………………………….19 [20] Li Y#, Tian C#, Wei Y#, Liu H, An N, Song K, SunY, Gao Y*, Gao Y*. Exploring the pharmacological mechanism of Naoxueshuoral liquid in the treatment of intracerebral hemorrhage through weighted geneco-expression network analysis, network pharmacological and experimentalvalidation.Phytomedicine.2023 Jan;108:154530.（SCI收录，一区，IF 6.656）.....................................................20 [21] Song Y, Jia Q, Guan X, Kazuo S, Liu J, Duan W, FengL, Zhang C*, Gao Y*. Herbal medicine for amyotrophic lateral sclerosis:A systematic review and meta-analysis. Front Pharmacol. 2022 Aug 31;13:946548.（SCI收录, 一区，IF5.988）.........................................................................................................................21 [22]Liu H#, An N#, Wang L#,Li Y, Song K, Sun Y*, Gao Y*. Protective effect of Xingnaojinginjection on ferroptosis after cerebral ischemia injury in MCAO rats andSH-SY5Y cells. J Ethnopharmacol. 2023 Jan 30;301:115836. （SCI收录，IF5.195）.........................................................................................................................22 [23] Xu Y, Hu Y, Xu S, Liu F, Gao Y*.Exosomal microRNAs as Potential Biomarkers and Therapeutic Agents for AcuteIschemic Stroke: New Expectations. Front Neurol. 2022 Jan 24;12:747380.（SCI收录，IF 4.086）......................................................23 [24] Song K#, Sun Y#,Liu H#, Li Y, An N, Wang L, Zhang H, Yang F, Xing Y*, GaoY*. Network Pharmacology and Bioinformatics Methods Reveal the Mechanism ofBerberine in the Treatment of Ischaemic Stroke.Evid Based Complement AlternatMed.2022 Jun 29;2022:5160329.（SCI收录，IF 2.65）.........................................24 [25] Pang YZ, Tang J, Zhang QH,Liang FZ, Fang G, Zhao C, Shang HC,Wang LY*, Wang YP*.Treatment of Psoriasis Vulgaris with MedicatedThread Moxibustion of Zhuang Medicine: A Multicenter Randomized, ParallelControlled Trial.Chin J Integr Med. 2022 Mar;28(3):208-214.（SCI收录，IF2.626）.........................................................................................................................25 3. 肾脏病、内分泌、风湿免疫方向 [26] Huang W#, Hickson LJ, Eirin A, Kirkland JL, Lerman LO*. Cellular senescence: the good, the bad andthe unknown. Nat Rev Nephrol.2022 Oct;18(10):611-627. （SCI收录，一区, IF 42.439）.................................................................................26 [27] Zheng Q#, Wang Y, YangH, Sun L, Zhang P, Zhang X, Guo J, Liu Y*, LiuWJ*. Cardiac and Kidney Adverse Effects of HIF Prolyl-HydroxylaseInhibitors for Anemia in Patients With CKD Not Receiving Dialysis: A SystematicReview and Meta-analysis. Am J Kidney Dis. 2022 Nov 14:S0272-6386(22)01014-9.（SCI收录，一区,IF 11.072）.......................................................................................................................27 [28] Huang, W#., Zhu, X. Y., Lerman, A.,Lerman, L. O*. Extracellular Vesicles asTheranostic Tools in Kidney Disease. Clin J Am Soc Nephrol.2022 Mar 8;17(9):1418-1429.（SCI收录，一区，IF 10.614）............................................28 [29] Liu CH,Pan ZS,Wu ZL,TangKJ,Zhong YD,Chen YJ,Xiao XX,Guo JY ,Duan SW,Cui TQ,Zhong GC,Yang ZF*,Zhong C*,LinS *,Gao Y*. Hepatic SIRT6 modulates transcriptional activities of FXR toalleviate acetaminophen-induced hepatotoxicity. Cell Mol Gastroenterol Hepatol.2022;14(2):271-293. （SCI收录，一区, IF 8.797).................................................................................................................29 [30] Cai Y#, Feng Z#, Jia Q#, Guo J, Zhang P, Zhao Q,Wang YX, Liu YN*, Liu WJ*. Cordyceps cicadae Ameliorates RenalHypertensive Injury and Fibrosis Through the Regulation of SIRT1-MediatedAutophagy. Front Pharmacol. 2022 Feb 10;12:801094. （SCI收录，IF 6.0).................................................................................................30 [31]Feng G#, Li D#, Liu J#,Sun S*, Zhang P, Liu W, Zhang Y, Meng B*, Li J*, Chai L*.The Herbal Combination of Radix astragali, Radix angelicae sinensis, and Caulislonicerae Regulates the Functions of Type 2 Innate Lymphocytes and MacrophagesContributing to the Resolution of Collagen-Induced Arthritis.FrontPharmacol.2022 Jul 19;13:964559. （SCI收录，一区，IF 5.81）.........................................................31 [32]Luo Q#, Wei R#, Cai Y#,Zhao Q, Liu Y*, Liu WJ*. Efficacy of Off-Label Therapy for Non-alcoholicFatty Liver Disease in Improving Non-invasive and Invasive Biomarkers: ASystematic Review and Network Meta-Analysis of Randomized ControlledTrials.Front Med (Lausanne).2022 Feb 25;9:793203. （SCI收录，一区，IF 5.1）.......................................................................................................................32 [33]Dong Z, Dai H, Liu W, Jiang H, Feng Z, Liu F,Zhao Q, Rui H, Liu WJ*, Liu B*. Exploring the Differences in MolecularMechanisms and Key Biomarkers Between Membranous Nephropathy and LupusNephritis Using Integrated Bioinformatics Analysis. Front Genet. 2022 Jan3;12:770902. （SCI收录, IF 4.8）......................33 [34]Luo Q, Cai Y, Zhao Q, Jiang Y, Tian L, Liu Y*,Liu WJ*. Renal Protective Effects of Melatonin in Animal Models ofDiabetes Mellitus-Related Kidney Damage: A Systematic Review and Meta-Analysis.J Diabetes Res. 2022 Jun 14;2022:3770417. （SCI收录, IF 4.1）..................................................................................................34 [35] Sun RX, Huang WJ*, Xiao Y, Wang DD, Mu GH,Nan H, Ni BR, Huang XQ, Wang HC, LiuYF, FuQ*, Zhao JX*. (2022). Shenlian (SL)Decoction, a Traditional Chinese Medicine Compound, May Ameliorate BloodGlucose via Mediating the Gut Microbiota in db/db Mice.J Diabetes Res.2022 Feb9;2022:7802107. （SCI收录，IF 4.061）...................................................................................................................35 [36] Jia Q, Guo J, Cai Y, Huang W, Zhu Z, Xia C, Guo K,Shang H, Liu Y*, & Liu W*. The Effectiveness and Safety ofAbelmoschus manihot in Treating IgA Nephropathy: A Systematic Review andMeta-Analysis.Evid Based Complement Alternat Med.2022 Oct 5;2022:9730753. （SCI收录，IF 2.65）.........................................................36 4. 循证评价方向 [37] Cui HR, Zhang JY*, Cheng XH, Zheng JX, ZhangQ, Zheng R, You LZ, Han DR*, Shang H*. Immunometabolism at the serviceof traditional Chinese medicine.Pharmacol Res.2022 Feb;176:106081. (SCI收录，一区，IF 10.3)..........37 [38] Hou Z, Yang X, Li Y, Chen J*,Shang H*. Electroacupuncture Enhances Neuroplasticity by Regulatingthe Orexin A-Mediated cAMP/PKA/CREB Signaling Pathway in Senescence-Accelerated Mouse Prone 8(SAMP8) Mice. Oxid Med Cell Longev. 2022 Feb 4;2022:8694462. (SCI收录，一区，IF 7.37)..............................38 [39] Chen K, Li G, Cui H*,Du Y, Zheng J, Zhang Q, Li F#, Shang H#,Lei H#. Systems pharmacology and GC-MS metabolomics revealthe efficacy and mechanisms of zedoary oil on acute liver injury induced byoxidative stress. Phytomedicine.2022 Sep;104:154295. doi:10.1016/j.phymed.2022.154295. Epub 2022 Jul 1. (SCI收录，一区， IF 6.656).......................................................................................................39 [40] Wang Q, Chen G, Chen X, LiuY, Qin Z, Lin P*, Shang H, YeM, He L*, Yao Z.* Development of a three-step-based novel strategyintegrating DMPK with network pharmacology and bioactivity evaluation for thediscovery of Q-markers of traditional Chinese medicine prescriptions: Danloutablet as an example.Phytomedicine. 2023 Jan;108:154511. (SCI收录， IF 6.656).....................................................................40 [41] Zheng R#, Sun Y#, Zhang X, Zhao C, Wang P,Chen S, Chen Z, Qiu R, Liang A*, Shang H*. Clinical features ofadverse events associated with Xiyanping-Ribavirin combination: A systematicreview.J Ethnopharmacol.2022 Jun 28;292:115076.（SCI收录，IF5.2）...........................................................................................................41 [42] Lai T, Guan Y, Men S, Shang H, Zhang H*. ResNet forrecognition of Qi-deficiency constitution and balanced constitution based onvoice. Front Psychol.2022 Dec 5;13:1043955. doi: 10.3389/fpsyg.2022.1043955.（SCI收录，IF 4.755）........................................................................................................................42 [43] LiuR#, Cao X#, Liang Y, Li X, Jin Q, Li Y, DuH, Zao X*, & Ye Y*. Downregulation of ST6GAL1 Promotes Liver Inflammation and PredictsAdverse Prognosis in Hepatocellular Carcinoma.J Inflamm Res.2022 Oct10;15:5801-5814.（SCI收录，IF 4.631）............................................................................................43 [44] ZhuH#, Li M#,Tian C, Lai H, Zhang Y, Shi J, Shi N, Zhao H, Yang K, Shang H,Sun X*,Liu J*, Ge L*,Huang L*. Efficacy and safety ofchinese herbal medicine for treating mild or moderate COVID-19: A systematicreview and meta-analysis of randomized controlled trials and observationalstudies. Front Pharmacol. 2022 Sep 7;13:988237. （SCI收录，IF 2.728）.....................................................................44 [45] QiuR, Zhong C, Wan S, Zhang Y, Wei X, Li M, Hu J, Chen S, Zhao C, Chen Z,Chen J*, Shang H*.Developing a core outcome set for assessing clinical safety outcomes ofcardiovascular diseases in clinical trials of integrated traditional Chinesemedicine and Western medicine: study protocol. Trials. 2022 Mar 28;23(1):239.doi: 10.1186/s13063-022-06166-3. （SCI收录，IF 2.728）..........................................45 [46] ZhangY, Guo S, Wang C, Liu X, Liu Y, Shang H,Yang P, Wang L, Zhai J, Li X*, JiaY*. Acupuncture for prostatectomyincontinence: study protocol for a multicenter single-blind randomized parallelcontrolled trial. Trials. 2022 Jan 4;23(1):9.（SCI收录，IF 2.728）............................................................................................................46 5. 中药药理及作用机制方向 [47] Ling-YW#, Gui-Y X#, Huan X, Xiao-HW, Ya-N W，Sheng L*.(+)(-)-Yanhusamides A?C, three pairs ofunprecedented benzylisoquinoline-pyrrole hetero-dimeric alkaloid enantiomersfrom Corydalis yanhusuo. Acta Pharm. Sin. B, 2022, (SCI收录，一区，IF 14.903)............................................................................................47 [48] Song M,Chen ZJ ,Qiu RA ,Zhi TW,Xie WM ,Zhou YY ,LuoNH,Chen FQ,Liu F,Shen CP ,Lin S* ,Zhang FX*,GaoY*,Liu CH*. Inhibition ofNLRP3-mediated crosstalk between hepatocytes and liver macrophages bygeniposidic acid alleviates cholestatic liver inflammatory injury. Redox Biol.2022 Jul 14;55:102404. (SCI收录，一区，IF 10.787).................................... ...................................................................48 [49] Wang L*, Wang X, Lv X, JinQ, Shang H, Wang CC, Wang L*. Theextracellular Ero1α/PDI electron transport system regulates plateletfunction by increasingglutathione reduction potential. Redox Biol. 2022Apr;50:102244.（SCI收录，IF10.787）..........................................................................................................49 [50] Xia GY, Wang LY, Xia H, Wu YZ, Wang YN, Hu HY*, LinS*. Circularly polarized luminescence of talarolactones (+)/(?)-A and(+)/(?)-C: The application of CPL-calculation in stereochemical assignment.Chin. Chem. Lett., 2022, 33: 4253–4256. (SCI收录, 一区, IF 8.455)..............................................................................50 [51] Wu YZ, Zhang Q, Wei XH, Jiang CX, Li XK, ShangHC*,Lin S*. Multiple anti-inflammatory mechanisms of Zedoary Turmeric OilInjection against lipopolysaccharides-induced acute lung injury in rats elucidatedby network pharmacology combined with transcriptomics.Phytomedicine.2022Nov;106:154418.(SCI收录，一区, IF 6.656)..........................................................51 [52] Zhang N#, Wu YZ#, Zhong WC, Xia GY ,Xia H, WangLY, Wei XH, Li Y, Shang H, He HW *,LinS*. Multiple anti-non-alcoholic steatohepatitis (NASH) efficacies ofisopropylidenyl anemosapogenin via farnesoid X receptor activation andTFEB-mediated autophagy.Phytomedicine.2022 Jul 20;102:154148.( SCI收录，一区，IF6.656)............................................................................................................................52 [53] Li Q#, Zhang T#, Wang Y#, Yang S, Luo J, Fang F, Liao J, Wen W*, Cui H*, Shang H*.Qing-Wen-Jie-ReMixture Ameliorates Poly (I:C)-Induced Viral Pneumonia Through Regulating theInflammatory Response and Serum Metabolism. Front Pharmacol. 2022 Jun15;13:891851. doi: 10.3389/fphar.2022.891851. PMID: 35784698（SCI收录，一区,IF 5.988）..................................................................53 [54] Cao X#, Liang Y#, Liu R#, Zao X, Zhang J,Chen G, Liu R, Chen H, He Y, Zhang J*, Ye Y* . Uncovering the PharmacologicalMechanisms of Gexia-Zhuyu Formula (GXZY) in Treating Liver Cirrhosis by anIntegrative Pharmacology Strategy.Front Pharmacol.2022 Mar 7;13:793888.（SCI收录，一区,IF 5.988）........................... 54 [55] Chen Z#, Zhao M#, You L#, Zheng R,Jiang Y, Zhang X, Qiu R, Sun Y, Pan H, He T,Wei X, Chen Z, Zhao C*, Shang H*. Developing an artificialintelligence method for screeninghepatotoxic compounds in traditional Chinese medicine and Western medicinecombination. Chin Med. 2022 May 17;17(1):58. doi:（SCI收录，IF4.546）.........................................................................................................................55 [56] CaoX#, Chen H#, Li Z#, Li X, Yang X, Jin Q, Liang Y, Zhang J, Zhou M, ZhangN, Chen G*, Du H*, Zao X*, & YeY*. Network pharmacology and in vitroexperiments-based strategy to investigate the mechanisms of KangXianYiAiformula for hepatitis B virus-related hepatocellular carcinoma.FrontPharmacol.2022 Sep 5;13:985084.（SCI收录，IF 5.988）.......................................................................56 [57] Wang LY,Xia H, Wu YZ, WangYN,Lin PC*,Lin S*. SecoyanhusamineA, an oxidatively ring-opened isoquinoline inner salt from Corydalisyanhusuo.Front Chem.2022 Feb 1;9:831173.（SCI收录，IF 5.545)..................................................57 [58] Wang M#, Li J#, Yin Y#, Liu L, Wang Y, Qu Y, HongY, Ji S, Zhang T, Wang N, Liu J, Cao X, Zao X*, & Zhang S*. Network pharmacology and in vivoexperiment-based strategy to investigate mechanisms of JingFangFuZiLiZhongformula for ulcerative colitis.Ann Med.2022 Dec;54(1):3219-3233. （SCI收录，IF5.348） ......................................................................................................................................58 [59] Zhang Q#, Wu YZ#, Ge MX, Xia GY, Xia H, WangLY, Wei XH, He HW*,Lin S*. Paeoniflorin-free subfraction of Paeonialactiflora Pall. shows the potential of anti-hepatic fibrosis: an integratedanalysis of network pharmacology and experimental validation.J Ethnopharmacol.2022 Dec 5;299:115678. （SCI收录，IF5.195）.....59 [60] Wu YZ#, Xia GY#, Xia H, Wang LY, Wang YN,LL, Shang H*,Lin S*. Seco and Nor-seco isodhilarane-type meroterpenoidsfrom Penicillium purpurogenum and the configuration revisions of relatedcompounds.J Nat Prod.2022 Jan 28;85(1):248-255. （SCI收录，IF4.803）............................................................................................60 [61] Xia GY#,Fang DJ#,Wang LY, Xia H, Wang YN, ShangH*,Lin S*. 13,13a-seco-protoberberines from the tubers of Corydalisyanhusuo and their anti-inflammatory activity. Phytochemistry.2022Feb;194:113023. （SCI收录，IF4.004）...............61 [62] Chen M#, Zhu H#, Zhu Q, Wu X, Zhou Y, Gao R, Shi M, Zhang T, Yin T, Zhang H*,Shang H*, Li X*. Citri Reticulatae Pericarpiumalleviates postmyocardial infarction heart failure by upregulating PPARγexpression. Clin Exp Pharmacol Physiol. 2022 Jun;49(6):661-673. （SCI收录，IF2.963）...................................................62 [63] Lin S, Chen H, Nie B,Jiang C, Yang H, Wang Q*, Yuan Z*. Sleep Breath.Raw Pinelliae Rhizoma:examination of sedative and hypnotic effects in mice and chemicalanalysis.Sleep Breath.2022 Sep 27.（SCI收录，IF2.655）....................................63 [64] Wang J#, Cao X#,Deng S#, Wang B, Feng J, Meng F, Xu H, Wang S, Zao X*, Li H*, Ye Y*.Effect of liver cirrhosis on erectile function in rats: A study combiningbioinformatics analysis and experimental research.Andrologia.2022Apr;54(3):e14352. （SCI收录，IF2.532）............................................................................................64 [65] Zhang Y#, Xia GY#, Wu YZ, Wei XH, Xia H,Wang LY, Lin PC, Wang YN, Chen LX*,Lin S*. Two new nor-secoisodhilarane-type meroterpenoids from the endophytic fungus Penicilliumpurpurogenum. Chem Biodivers.2022 Jul;19(7):e202200403. （SCI收录，IF2.275）............................................................................................65 [66] Sun KH, Yang MF, Xu XR, LiY, Gao Z, Zhang QY, Li H, Wang SQ, Lou LX,Wu AM*, Jin QS, Wu SX*,Nie B*.Comparative Pharmacokinetics of Seven Major Compounds in Normaland Atherosclerosis Mice after Oral Administration of Simiao Yong'anDecoction.Evid Based Complement Alternat Med.2022 Apr 28;2022:4604601. （SCI收录，IF1.984）............................................................................................66 [67] WangLY#,XiaGY#,WangM,Wu YZ,Wang YN,Chai LM*,Lin S*. Penicipurate A, a new polyketidederivative from the endophytic fungus Penicillium purpurogenum. J Asian NatProd Res.2022 Jul 19;1-7.（SCI收录，IF 1.610）.................................67 备注：#：共同第一作者；*：通讯作者
中 文 文 章 1. 心血管病方向 [1] 张倩,卫晓红,陈洁,吴雪芬,夏小凤,武玉卓,王玲燕,夏欢,夏桂阳,林生*,商洪才*.慢性心力衰竭常用动物模型的研究进展及其在中医药研究中的应用[J/OL].中国中药杂志:1-13[2022-12-27]. 20220918.201.................................68 [2] 张国霞,苏鑫,商洪才,邢雁伟*.从“毒损心络”探析肿瘤心脏病的中医病机[J].中医杂志,2022,63(14):1394-1396.DOI:10.13288/j.11-2166/r.2022.14.016............................................................................................69 [3] 刘文静,张晓雨,韩松洁,代倩倩,商洪才*.免疫检查点抑制剂引起的心血管动脉粥样硬化事件及中西医防治策略[J].自然杂志,2022,44(02):117-125. .....................................................................................................................................70 [4] 贾冬冬,王曼曼,高毅洁,国倩倩,杨睿,张馨月,张冬梅*.血府逐瘀汤对心血管疾病炎症介质影响的Meta分析[J].世界中医药,2022,17(22):3168-3173+3179. ...................................................................................................................................71 [5] 王曼曼,贾冬冬,张馨月,娄利霞,吴爱明,赵一舟,国倩倩,杨睿,张冬梅*.血府逐瘀胶囊对动脉粥样硬化模型小鼠主动脉病变及CD47、PPAR-γ、NR1H3表达的影响[J].中医杂志,2022,63(17):1673-1678+1684.DOI:10.13288/j.11-2166/r.2022.17.014..........................................................................................................72 [6] 纪晓迪,吴爱明*,吕梦,杨丁,娄利霞,聂波,赵久丽,赵明镜*.基于miRNA-133a/TGF-β1/Smads信号通路探讨芪苈强心胶囊对心肌梗死大鼠心肌纤维化的作用机制[J].海南医学院学报,2022,28(21):1608-1613.DOI:10.13210/j.cnki.jhmu.20220331.002.......................................................................................................73 [7] 吕梦,纪晓迪,刘珂珂,娄利霞,聂波,赵久丽,吴爱明*.稳心颗粒对心肌梗死大鼠缝隙连接蛋白43和内质网应激通路基因表达的影响[J].中国现代中药,2022,24(04):644-651.DOI:10.13313/j.issn.1673-4890..........................................74 [8] 白云绮,李慧,高照,范冬冬,娄利霞,吴爱明,孙克寒,商洪才,聂波*.酒制豨莶草和生豨莶草对缺氧损伤的H9c2心肌细胞保护作用的比较研究[J].世界中医药,2022,17(06):779-783+789.................................................................................75 [9] 张婷,马喆,赵久丽,金秋硕,娄利霞*.生脉注射液对心肌缺血再灌注损伤大鼠线粒体融合素2的影响及保护作用[J].中西医结合心脑血管病杂志,2022,20(11):1959-1964.....................................................................................76 [10] 蒋洋洋,谢颖桢,赵明镜*.从“心主神明”理论探讨心血管疾病与认知功能障碍的关联[J].北京中医药大学学报,2022,45(04):334-341...............................................................................................................................77 [11] 滕宇,赵明镜*,王蕾,陆梓雯,蒋洋洋.基于数据挖掘探讨慢性心力衰竭伴焦虑、抑郁的中药用药规律[J].中西医结合心脑血管病杂志,2022,20(07):1160-1166.............................................................................................................................78 [12] 张楠楠,赵明镜,孔令旗,张艺璇,王尔玉,修晟尧,李天力,刘小芸,贺小芳,常佩芬*.exoRBase数据库外泌体基因在冠心病中的差异表达及意义[J].中国动脉硬化杂志,2022,30(01):36-42............................................................................79 2. 脑血管病方向 [13]许岩,李丝雨,李亚楠,宋玉,万小青,翟华强*,商洪才,金世元.化风丹联合基础方案治疗中风有效性和安全性Meta分析[J].中国药业,2022,31(08):112-116................................................................................................................................80 [14]林宏远,方锐,张泽鑫,周月,王珊珊,蒋祁零,宋祯彦,梅志刚,葛金文*,商洪才*.基于网络药理学和分子对接的脑泰方防治高血压脑小血管病作用机制研究[J].世界科学技术-中医药现代化,2021,23(12):4364-4373..............................81 [15] 王宏杰,朱陵群,张玉侠,孙艳平*,谭立萍,马超.精神分裂症患者出院后1年内再住院风险因素[J].慢性病学杂志,2022,23(11):1682-1685.DOI:10.16440/J.CNKI.1674-8166.2022.11.21. ...........................................................................82 [16] 王海若,阎明源,高梦霞,刘凤智,温春丽,朱陵群*.朱陵群从心肝肾论治慢性失眠的用药规律[J].中医药导报,2022,28(04):138-142.DOI:10.13862/j.cn43-1446/r.2022.04.028.................................................................................................83 [17] 高梦霞,阎明源,王海若,卓于迪,陈燚,温春丽,常静玲,高颖,朱陵群*.依达拉奉超适应症治疗病毒性脑炎的Meta分析及GRADE评价[J].药物评价研究,2022,45(05):965-974........................................................................................84 [18] 刘蕊嘉,宋连英,朱陵群,哈春云,于旭东,阎明源,张立苹*.脑卒中后认知功能障碍的诊疗进展及影像学特征评价[J].中西医结合心脑血管病杂志,2022,20(10):1811-1814.....................................................................................85 [19] 高梦霞,阎明源,王海若,刘凤智,温春丽,常静玲,高颖,朱陵群*.氯吡格雷联合阿托伐他汀对脑梗死患者炎症反应、血液流变学和凝血功能影响的系统评价[J].中国医院用药评价与分析,2022,22(05):595-602.DOI:10.14009/j.issn.1672-2124.2022.05.019...........................................86 [20] 王宏杰,朱陵群*,王智民,李先宾,张玉侠,孙艳平,谭立萍,夏立杰.再住院精神分裂症患者药物依从性相关因素分析[J].中国当代医药,2022,29(16):129-132.............................................................................................................................87 [21]李文慧,朱陵群,郭蓉娟*.探讨新冠肺炎疫情下应激性失眠的中医治疗思路[J/OL].辽宁中医杂志:1-10[2023-01-01].http://kns.cnki.net/kcms/detail/21.1128.R.20220712.1202.014.html....................................................................88 [22]王宏杰,孙艳平*,朱陵群,王智民,李先宾,张玉侠,谭立萍,夏立杰,杨天龙,马超,刘欣然.精神分裂症患者再住院相关因素分析[J].慢性病学杂志,2022,23(08):1201-1204+1208.DOI:10.16440/J.CNKI.1674-8166.2022.08.21……....89 [23]高梦霞,常静玲*,王海若,阎明源,刘凤智,陈燚,卓于迪,朱陵群.从“五脏失和，浊毒郁闭”论治失眠[J].江苏中医药,2022,54(08):17-19.DOI:10.19844/j.cnki.1672-397X.2022.08.007.…………………………………………..…...90 [24]王思锦,张明慧,马喆,李婷婷,高永红,娄利霞,高颖*.松龄血脉康胶囊治疗缺血性中风的Meta分析[J].长春中医药大学学报,2022,38(09):992-997.DOI:10.13463/j.cnki.cczyy.2022.09.012. ……………………………………..…...91 [25] 李传朋,高颖,高永红,蒋萍,董兴鲁*.脑缺血再灌注损伤中钙超载相关通路研究进展[J].中国医药导报,2022,19(12):46-50. ………………………..…...92 [26] 田梅静,高晨艳,郑明翠,和雁南,王蓬文*.基于nNOS/CAPON相互作用探讨参枝苓口服液对拟散发性AD小鼠海马突触的影响[J].中国比较医学杂志,2022,32(08):1-10..............................................................................................93 3. 循证评价方向 [27] 蒋寅,张心怡,赵梦竹,关之玥,魏旭煦,靳英辉,商洪才,赵晨*.融入辨治逻辑点的中医辅助诊疗平台医师信任度预调查分析[J].医学新知,2022,32(06):417-423........................................................................................94 [28]李玲,刘艳梅,谭婧,王雯,姚明宏,任燕,黄伟,夏庆,张英,梁晓,梁繁荣,商洪才,孙鑫*.构建中西医结合诊疗环境下中医药临床疗效评价一体化方法体系[J/OL].中国中西医结合杂志:1-7[2022-12-27]. 20221102....................................95 [29] 施秀青,阎思宇,黄桥,李绪辉,王永博,马文昊,商洪才*,靳英辉*.真实世界研究：弥合临床实践指南与临床决策之间的距离[J/OL].协和医学杂志:1-18[2022-1227].20221009.1725.002.html............................................................96 [30]吴圣贤,樊钦华,苏文全,张立山,张伟,方邦江,周凌,龙友余,张业清,王檀,熊旭东,曲妮妮,石克华,肖伟,商洪才*,王永炎*.银翘清热片临床疗效观察[J].生物医学转化,2022,3(03):82-92..............................................................................97 [31] 郭嘉琪,龙囿霖,林春滢,王心怡,郭琼,林逸飞,黄进,杨克虎,章仲恒,徐畅,商洪才*,杜亮*.Meta流行病学研究的报告规范解读[J].中国循证医学杂志,2022,22(09):1071-1079.....................................................................................98 [32] 周奇,李沁原,刘雅莉,罗征秀,张卫社,陈彤,李国保,商洪才,杨克虎,张波,陈耀龙*,张抒扬.罕见病指南的制订：现状、挑战与机遇[J/OL].协和医学杂志:1-13[2022-12-27].20220822.0944.002..........................................................99 [33]付静,商洪才*.基于混合方法研究中的探索性序列设计探讨民间特色诊疗技术临床疗效评价思路[J].中华中医药杂志,2022,37(07):3957-3960...........100 [34]龙囿霖,林春滢,郭嘉琪,王心怡,杨柳,程祎凡,黄进,杨克虎,章仲恒,徐畅,商洪才*,杜亮*.Meta流行病学的产生与发展[J].中国循证医学杂志,2022,22(06):716-721.............................................................................................................101 [35] 李红艳,施秀青,郭静,张蓉,周婕,靳英辉,商洪才*.临床实践指南实施性促进研究之五：中医/中西医结合临床实践指南与专家共识的实施性评价[J].医学新知,2022,32(03):161-169.................................................................................102 [36] 尤良震,张心怡,关之玥,崔鹤蓉,陈昭,张晓雨,武玉卓,商洪才*.从循证毒理学产生发展谈中药循证毒理学的理念与方法[J].中国中药杂志,2022,47(17):4823-4828.20220530.601.......................................................103 [37]张晓雨,万思琦,刘文静,韩松洁,孙杨,张晶晶,尤良震,武玉卓,赵晨,商洪才*.迈入高效精准新时代:中医药防治重大疾病循证研究的回顾与展望[J].中国科学:生命科学,2022,52(06):823-831................................................................104 [38] 荣红国,董玥,于蔚洁,商洪才,刘建平,费宇彤*.政策工具视角下我国中药注射剂发展政策研究[J].中国药房,2022,33(08):917-922...............................105 [39]陈莹,常静玲,李新龙,刘岩,张晶晶,张学成,代恒恒,商洪才*.基于CiteSpace的近20年蚓激酶相关研究的文献计量学分析[J].世界科学技术-中医药现代化,2022,24(01):388-397.....................................................................................106 [40]陈莹,常静玲,代恒恒,张凯歌,张晶晶,张学成,万思琦,关之玥,胡明智,刘岩,商洪才*.精准医学模式下的母方案篮式试验设计方法及其在中医药领域中的应用[J].中国循证医学杂志,2022,22(04):483-489..........................................107 [41] 司宜蓓,郭静,王永博,李绪辉,黄桥,王家莹,靳英辉*,商洪才*.临床实践指南实施性促进研究之四：中医/中西医结合指南知识图谱知识抽取、存储与实例展示[J].医学新知,2022,32(02):99-107............................................................108 [42]李新龙,刘岩,王宁,田贵华,商洪才*.方剂间相似性的量化表征方法及模型应用[J].中华中医药杂志,2022,37(04):2120-2124..........................................109 [43]向兴华,彭叶辉*,杨伟*,刘剑,刘大胜,纪鑫毓,雷舒杨,谢飞彪,杨纪雯,王丽颖,韩学杰,商洪才.顽固性高血压发生主要不良心血管事件患者的中医四诊信息可解释性研究——基于随机森林规则提取方法[J].中医杂志,2022,63(07):628-634.DOI:10.13288/j.11-2166/r.2022.07.006.............................................110 [44] 向兴华,彭叶辉*,杨伟*,刘剑,刘大胜,纪鑫毓,雷舒杨,谢飞彪,杨纪雯,王丽颖,韩学杰,商洪才.基于随机森林规则提取方法的顽固性高血压发生主要不良心血管事件患者的中医四诊信息可解释性研究[J/OL].中医杂志:1-7[2022-12-27]............................................................................................................................111 [45] 郭静,司宜蓓,王永博,高旷,黄桥,李绪辉,阎思宇,王家莹,张蓉,任相颖,靳英辉*,商洪才*.临床实践指南实施性促进研究之三：中医/中西医结合指南知识图谱框架设计[J].医学新知,2022,32(01):2-9..................................................112 [46] 夏鸿杰,赵峥嵘,郭静,黄桥,魏旭煦,周婕,任相颖,张蓉,靳英辉*,商洪才*.中医相关证据质量及推荐意见分级体系的系统评价[J].中国循证医学杂志,2022,22(02):187-195......................................................................................113 [47] 夏小凤,夏桂阳,武玉卓,夏欢,王玲燕,商洪才,林生*.中药痕量药效物质：中药创新药物的重要来源[J].中国中药杂志,2022,47(07):1705-1729. 20220210.201.........................................................................................................114 [48]张晶晶,刘岩,商洪才*.新时代中医药临床疗效评价的问题与策略[J].科学通报,2022,67(09):814-821..................................................................................115 [49] 商洪才.临床“有毒”中药数智融合研究新模式:中药循证毒理学的提出[J].科学通报,2022,67(02):118-124…………………………………………...116 [50] 李涵,邱瑞瑾,李京,孙杨,商洪才*.和而不同 存异求同——中医学对叙事医学发展的启示[J].叙事医学,2022,5(01):8-12..................................................117 [51] 王家莹,吴云,张继胜,商洪才*.引入叙事医学理念减少针灸循证研究中医患报告结局分歧的思考[J].叙事医学,2022,5(01):13-18....................................118 [52] 李新龙,朱爽,刘岩,杜元,郑坤.中医临床思维研究热点和趋势可视化分析[J].中国中医药信息杂志,2023,30(01):47-52.DOI:10.19879/j.cnki.1005-5304.202201389. ..........................................................................................................119 [53] 李玲,刘艳梅,谭婧,王雯,姚明宏,马玉,罗小超,廖星,刘岩,宋海波,温泽淮,孙鑫*.基于真实世界数据的中成药安全性评价模式构建[J].中国药物警戒,2022,19(01):18-22.DOI:10.19803/j.1672-8629.2022.01.04. …….…....120 4. 中药药理及作用机制方向 [54]白云绮,李慧,高照,范冬冬,娄利霞,吴爱明,孙克寒,商洪才,聂波*.酒制豨莶草和生豨莶草对缺氧损伤的H9c2心肌细胞保护作用的比较研究[J].世界中医药,2022,17(06):779-783+789...............................................................................121 [55] 王启航,陆瑞敏,陈萌*,张冬梅.4种脾虚造模法的横向对比研究[J].天津中医药,2022,39(02):238-2.43...................................................................................122 [56] 张慧杰,柴立民*,刘娟,张萍心,李晋玉,李东阳,孙嵩.基于JAK/STAT信号通路探讨红茴香注射液对类风湿关节炎小鼠的作用机制[J].北京中医药大学学报,2022,45(03):267-274......................................................................................123 [57] 贺晋芳,张沂,田思强,吴甜甜,高伟华,金译涵,张迪,柴立民,晏军*.补肾益肺消癥方干预特发性肺纤维化Ⅱ型肺泡上皮细胞间充质转化调控内质网应激的作用机制[J].世界中西医结合杂志,2022,17(01):1-5.DOI:10.13935/j.cnki.sjzx.220101.................................................................124 [58] 纪晓迪,杨丁,崔喜元,娄利霞,聂波,赵久丽,赵明镜,吴爱明*.芪苈强心胶囊对心肌梗死大鼠心脏IP3Rs/GRP75/VDAC1基因调控的机制研究[J/OL].海南医学院学报:1-18[2023-01-01].DOI:10.13210/j.cnki.jhmu.20221116.002......125 5. 药物分析方向 [59] 吴雪芬,卫晓红,武玉卓,夏桂阳,夏欢,王玲燕,商洪才,林生*.中药活性成分靶点确定及作用机制研究方法进展[J].中国中药杂志,2022,47(17):4565-4573.DOI:10.19540/j.cnki.cjcmm.20220330.201..................................................126 [60] 许宗颖,车晓彦,包小红,刘兴兰,张冬梅,陈萌*.基于特征图谱和含量测定的乌梅丸质量标准研究[J].中国药业,2022,31(11):73-78............................................................................................................................127 [61] 高照,许心蕊,金秋硕,孙浩,孙克寒,杨漫芳,张晴玥,李洋,娄利霞,吴爱明,聂波*.四妙勇安汤通过拮抗Ox-LDL脂代谢途径对ApoE~(-/-)小鼠动脉粥样硬化颈动脉斑块的影响[J].海南医学院学报,2022,28(14):1050-1058.DOI:10.13210/j.cnki.jhmu.20220325.002.............................................128 6. 中医理论方法 [62] 朱淼,张冬梅,张瑜,翟墨汀,孟珊珊,陈萌*.胆汁类药物的古今应用[J].中华中医药杂志,2022,37(09):5433-5436..............................................................129 [63] 张迪,张冬梅,陆瑞敏,吉静,许宗颖,王旭,陈萌*.基于“肺主行水”理论探究小青龙汤调节肺水转运蛋白的作用机制[J].中国实验方剂学杂志,2022,28(08):1-11.DOI:10.13422/j.cnki.syfjx.20220736..............................................130 [64] 李磊,刘姝伶,张冬梅,丁鹏,丁霞,康雷*.姜良铎应用桂枝加厚朴杏子汤治疗喘证经验[J].中医杂志,2022,63(03):212-215.DOI:10.13288/j.11-2166/r.2022.03.003..............................................................................................131 [65] 杨睿,梁晋普,张冬梅*.郭维琴辨治心肌炎经验[J].吉林中医药,2022,42(05):531-534..2022.05.010………………………..……….……..132 [66] 王艳鹏,孔令博*,林运霞,陈腾飞*,柴立民*.刘清泉教授基于“宗气”理论治疗喘脱危证临证经验[J].中国中医急症,2022,31(09):1459-1461..............133 [67] 郑慧娟,郭小乐,艾思南,田蕾,刘伟敬*,王耀献*.基于“内伤伏邪”理论探讨糖尿病肾病的发病机制[J].现代中西医结合杂志,2022,31(14):1992-199.134 [68] 李顺民,孙升云,占永立,方敬爱*,刘伟敬*,刘玉宁*.从脾论治肾脏病的思路与方法[J].中国中西医结合肾病杂志,2022,23(07):656-658. .......................135 [69] 童安荣,王琳,李平,方敬爱*,刘伟敬*,刘玉宁*.从肝论治肾脏病的思路与方法[J].中国中西医结合肾病杂志,2022,23(05):468-470. ...............................136 [70] 王耀光,郭立中,占永立,方敬爱*,刘伟敬*,刘玉宁*.从肺论治肾脏病的思路与方法[J].中国中西医结合肾病杂志,2022,23(03):280-282. ……….…......137 [71] 郭兆安,鲁盈,戴恩来,方敬爱*,刘伟敬*,刘玉宁*.从络论治肾脏病的思路与方法[J].中国中西医结合肾病杂志,2022,23(09):844-846. ...........................138 7. 肾脏病、内分泌、风湿免疫方向 [72] 董正华,李建民,刘宝利,方敬爱*,刘伟敬*,刘玉宁*.从六经论治肾脏病的思路和方法[J].中国中西医结合肾病杂志,2022,23(11):1032-1034. .................139 [73] 高亚斌,王耀献*,杨蕊冰,冯睿,郑慧娟,郭敬,王珍*.糖尿病肾脏病早期内热证与非内热证患者肠道菌群及脂多糖的相关性分析[J].中华中医药杂志,2022,37(03):1735-1739.................................................................................140 [74] 刘怡秀,王耀献*,柳红芳,郑慧娟.基于三焦理论应用清热消癥法辨治IgA肾病[J].环球中医药,2022,15(05):854-857...........................................................141 [75] 郭小乐,郑慧娟,田蕾,于博睿,郭敬,王耀献*.王耀献从胃肾相关论治2型糖尿病肾脏病[J].中医学报,2022,37(06):1214-1218.DOI:10.16368/j.issn.1674-8999.2022.06.223......................................142 [76] 周静威,孙万森,郭立中,陈洪宇,方敬爱*,刘伟敬*,刘玉宁*.从风论治肾脏病的思路与方法[J].中国中西医结合肾病杂志,2022,23(01):92-94...............143 [77] 周梦琪,郑慧娟,田蕾,于博睿,陶嘉茵,艾思南,刘伟敬,王耀献*.糖尿病肾病肾间质纤维化“肾络癥瘕聚散消长”病机内涵[J].中医学报,2022,37(02):293-298.DOI:10.16368/j.issn.1674-8999.2022.02.056…144 [78] 姜玉华,娄文娇,蔡雨孜,罗倩,刘玉宁,刘伟敬*.基于“肾络三态”理论浅述虫类药在肾络痹证中的应用[J].中华中医药杂志,2022,37(02):828-831..145 [79]郭小乐,艾思南,郑慧娟,孙卫卫,刘伟敬,王耀献*.辨机论治与组分中药[J].中国中西医结合肾病杂志,2022,23(10):930-931. ...................................146 [80] 孙鲁英,孙卫卫,周少峰,田蕾,张美龄,艾思南,郑慧娟,李垚锬,李丹婷,刘伟敬,周静威,王珍,王耀献*.中医药防治慢性肾脏病的临床证据及效应机制[J].生物医学转化,2022,3(03):31-44+63. ..............................................................147 [81] 唐靖怡,张娉娜,姜玉华,董兆珵,耿运玲,刘伟敬*,刘玉宁*.小柴.胡汤群方在肾脏病中的临床应用[J].吉林中医药,2022,42(09):1016-1020.DOI:10.13463/j.cnki.jlzyy.2022.09.007. ............................................................................148 [82] 闫占峰,孔令博,王景尚,刘宝利,徐愿,刘应科,王萍,张苍,刘伟敬,邹大威,杨国旺,李得民,陈江,莫美,朱勇,王彬,张霄潇*.中医药临床优势病种的探索与认识——中华中医药学会临床优势病种研讨系列青年沙龙[J].中国实验方剂学杂志,2023,29(01):202-208.DOI:10.13422/j.cnki.syfjx.20230193. …....149 [83] 陈弘东,王耀献*,刘伟敬,郭敬,李璐璐,李军,贺仲晨*.2型糖尿病合并肥胖的中医证素特点研究[J/OL].辽宁中医药大学学报:1-21[2022-12-27].http://kns.cnki.net/kcms/detail/21.1543.R.20220801.1846.002.html...................150 [84] 陈弘东,王耀献,刘伟敬,郭敬,张超,孙浩,娄文娇,贺仲晨*.平腑调代方对肥胖2型糖尿病小鼠脂代谢和炎症及氧化应激水平的影响[J].中国医药,2022,17(08):1238-1241. ..................................................................................................151 [85] 郭科婷,于国泳,蔡雨孜,郑慧娟,王耀献,吕仁和,刘玉宁*,刘伟敬*.维生素E治疗糖尿病肾病临床研究的Meta分析[J].中国中西医结合肾病杂志,2022,23(06):492-498. ..........................................................................................................152 [86] 娄文娇,郭敬,张帆,姜玉华,罗倩,王耀献,吕仁和,刘玉宁*,刘伟敬*.黄连素(小檗碱)治疗早期糖尿病肾病有效性和安全性系统回顾及Meta分析[J].中国中西医结合肾病杂志,2022,23(06):510-513. ......................................................153 [87] 郑慧娟,周梦琪,刘伟敬,王耀献*.中医药治疗对糖尿病肾脏病患者尿液足细胞相关指标影响的Meta分析[J].世界中西医结合杂志,2022,17(02):223-231.DOI:10.13935/j.cnki.sjzx.220203. .............................................................154 [88] 王婷婷,李嘉萌,马贝贝,梁润晨,黄为钧,倪博然,吕仁和,赵进喜,王世东,王志斌,王晶*.止消温肾宁颗粒对糖尿病肾病大鼠的治疗作用及机制研究[J].中华中医药杂志,2022,37(04):2241-2245. ..........................................................155 [89]肖遥,傅强*,赵进喜,孙瑞茜,黄为钧,刘轶凡,刘媛媛.基于网络药理学的“人参-黄连-三七”药串治疗2型糖尿病胰岛素抵抗合并非酒精性脂肪肝的机制[J].世界中医药,2022,17(01):22-30. ..............................................................156 [90] 韦杰,张萍心,李东阳,张慧杰,美依尔·欢地克,柴立民*.基于数据挖掘分析吕仁和教授治疗糖尿病的用药规律[J].吉林中医药,2022,42(10):1207-1210.DOI:10.13463/j.cnki.jlzyy.2022.10.022. ........................................................157
|